HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

NCT06744556 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

AML

Interventions

DRUG: daunorubicin
DRUG: Venetoclax
DRUG: cytarabine
DRUG: azacitidine
DRUG: Homoharringtonine
DRUG: Idarubicin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China